Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 6 for:    "Alzheimer Disease" | "Lithium carbonate"

LIWA for Treatment of Alzheimer Patients (LIWA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02204969
Recruitment Status : Unknown
Verified January 2015 by American Society Of Thermalism And Climatology Inc.
Recruitment status was:  Recruiting
First Posted : July 31, 2014
Last Update Posted : January 6, 2015
Sponsor:
Information provided by (Responsible Party):
American Society Of Thermalism And Climatology Inc

Brief Summary:
The thermal therapy combined with magnetic fields and ozone has a direct effect on patients with dementia and Alzheimer's with a regression of more than 60% of them

Condition or disease Intervention/treatment Phase
Alzheimer Disease Dietary Supplement: Lithia water Device: Transcranial Magnetic stimulation Phase 1 Phase 2

Detailed Description:

Alzheimer's disease (AD) is the leading cause of dementia and cognitive deteriorating in the advanced age. This main target of this study is to determine the safety and efficacy of transcranial magnetic stimulation (TMS) using novel coil design (H2) for stimulation of deep brain structures concomitantly with regular treatment in Alzheimer's disease (AD) patients. TMS acts by generating magnetic fields in the brain which simulate neuro-chemical changes and stimulate neuronal activity translating into increased secretion of growth factors such as brain derived neurotropic factor (BDNF). Hence it is postulated that TMS will have a positive effect on the cognitive and behavioral symptoms of patients with AD and may ameliorated the progression of the disease. The treatment is non-invasive, with no significant side effects, and no need of hospitalization or anesthesia. The trial is phase II double blind study including 100 AD patients ages between 50 to 80 with mild or moderate AD (Mini Mental State Examination [MMSE] 16 to 26) divided into 3 groups. All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks. Patients will be evaluated before the treatments, after 8 weeks of treatment and after another 8 weeks without treatment. The evaluations will include cognitive function according to ADAS-COG and MMSE, Activity of daily living (ADL) functions according to ADSC-ADL, behavioral function according to the Neuropsychiatric Inventory (NPI), depression according to the Cornell Scale for Depression in Dementia (CSDD), care giver satisfaction according to the RUD LITE scale and computerized cognitive evaluation according to the NEXING battery. We expect that the cognitive, behavioral and ADL functions will improve better in the study group as compared to the Sham treated group. From previous trial of TMS in neurological patients, although not in AD, we anticipate that adverse events rate will be similar between groups proving the safety of deep TMS treatment in patients with AD. In case our hypothesis will be proven, deep TMS treatment will be added as an important modality to the conventional therapy of AD patients.

All patients will be received 500 mcg/d of lithium as supplement nutritional in form spring mineral water


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Transcranial Magnetic Stimulation (TMS) and Lithium Water for Treatment of Alzheimer Patients
Study Start Date : January 2015
Estimated Primary Completion Date : June 2015
Estimated Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Drinking Water

Arm Intervention/treatment
Sham Comparator: Transcranial magnetic stimulation
All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
Device: Transcranial Magnetic stimulation
All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
Other Name: novel coil design (H2)

Placebo Comparator: lithia water
  • Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water
  • Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels
Dietary Supplement: Lithia water
  • Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water
  • Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels
Other Name: pring Mineral water




Primary Outcome Measures :
  1. Cognitive functioning score by ADAS-COG [ Time Frame: 4 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women aged 50-85.
  2. Diagnosed with Alzheimer's disease for at least half a year (by the DSM-IV criteria).
  3. Scored 16-26 on the MMSE.
  4. Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks.
  5. Existence of a routine therapist for changes or adverse effects reports.
  6. Existence of Alzheimer diagnosis by CT or MRI tests.
  7. Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.
  8. Gave their oral and written consent to participate in the trial.

Exclusion Criteria:

  1. An additional neurological disorder.
  2. Severe psychiatric disorder.
  3. Uncontrolled hypertension, beyond 170/110.
  4. History of epilepsy, seizure, or heat convulsion or History of epilepsy or seizure in first degree relatives.
  5. History of head injury or stroke.
  6. History of metal implants in the head (except dental fillings)or History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neuro stimulators, or any medical pumps.
  7. History of migraines in the last six months.
  8. History of drug or alcohol abuse.
  9. Inadequate communication with examiner.
  10. Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.
  11. Inability to sign a consent form.
  12. Leukemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02204969


Locations
Layout table for location information
United States, New Jersey
Gaviota Clinic Recruiting
Newark, New Jersey, United States, 07105
Contact: Garis Silega, Dr    862-229-4766    drsilega@aol.com   
Principal Investigator: Garis Silega, Dr         
Sponsors and Collaborators
American Society Of Thermalism And Climatology Inc
Investigators
Layout table for investigator information
Principal Investigator: Garis Silega, Dr American Society of Thermalism and Climatology

Layout table for additonal information
Responsible Party: American Society Of Thermalism And Climatology Inc
ClinicalTrials.gov Identifier: NCT02204969     History of Changes
Other Study ID Numbers: 822429989
First Posted: July 31, 2014    Key Record Dates
Last Update Posted: January 6, 2015
Last Verified: January 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Lithium Carbonate
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Antidepressive Agents
Psychotropic Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs